Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ypsomed & Adval in mold-making deal:

This article was originally published in Clinica

Executive Summary

Burgdorf-based Ypsomed has agreed to use the injection molding technology of fellow Swiss company Adval Tech Holding in the production of its injection pen and pen needle range. Ypsomed CEO Richard Fritschi said his company could reduce lead times and better standardise the product range by incorporating the Niederwangen company's expertise. Subassembly and components company Adval has been targeting penetration of selected new markets, including medtech and pharma. Its CEO, Jean-Claude Philipona, said the deal would result in added value throughout the entire value chain.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048948

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel